Skip to main content
Fig. 11 | BMC Pulmonary Medicine

Fig. 11

From: A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials

Fig. 11

The results of inverted funnel plots. a SAEs. b All-cause mortality. c FVC (L) absolute change from baseline. d FVC (% predicted)absolute change from baseline. e The proportion of patients with decline in FVC≥10% predicted. (PLA:Placebo; NIN:Nintedanib; PIR:Pirfenidone; SIL:Sildenafil; AMB:Ambrisentan; PAM:Pamrevlumab; BOS:Bosentan; MAC:Macitentan; IMA:Imatinib; GLPG:GLPG1690; SIM:Simtuzumab; WAR:Warfarin;PRM: PRM151;NAC:N-acetylcysteine.)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us